It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
Browsing: 988
The Nasdaq rose 5 points on Monday, due in part to recent happenings in the biopharmaceutical sector.